NEW YORK - Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced today the deployment of OpenClaw, an AI-enabled computational platform designed to support drug discovery and data analysis across its ...

The launch of OpenClaw™ establishes a centralized, high-performance platform capable of integrating preclinical and clinical datasets in real time, enabling faster and more efficient research ...

PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. Safety and tolerability findings included: No serious ...

PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations. (PRNewsfoto/Hoth Therapeutics Inc.) In addition, HT-001 ...

Hoth Therapeutics Inc. (NASDAQ: HOTH) on Wednesday announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, targeting rare and aggressive KIT-driven cancers. The ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. Jack will take on his fiercest foe yet in “Reacher” Season 4. The next season of Prime Video's popular action series, ...

Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another milestone for a candidate designed to complement cancer therapies. The open ...

Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets NEW YORK, Jan. 21, 2026 /PRNewswire/ -- ...

Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of sight to site activation and enrollment Near-term regulatory and ...

Heaven gained a special angel with the passing of Reda Lafave Hoth, Dec. 30 at her daughter’s home in South Carolina where she resided. Reda was born April 15, 1927 in Churbusco, NY to the late ...

Fintel reports that on November 17, 2025, D. Boral Capital maintained coverage of Hoth Therapeutics (NasdaqCM:HOTH) with a Buy recommendation. Analyst Price Forecast Suggests 242.86% Upside As of ...